# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia ...
https://ml-eu.globenewswire.com/Resource/Download/be52a7ec-2630-49c0-b374-88ae71352c87
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was a...
To gain an edge, this is what you need to know today.
U.S. labor market misses April expectations, signaling slower economic growth and potential interest rate cuts. Stocks rise, Tr...